All In Biotech

Free tool

FAERS Monitor: Anktiva

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761336 or its brand name (Anktiva, Nogapendekin Alfa Inbakicept-Pmln). Reports on generic versions are filed under their own applications.

Reports

49

Serious

23

47% of reports

Hospitalization

7

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neutropenia10
  • chills7
  • pyrexia6
  • dysuria5
  • pollakiuria5
  • anaemia4
  • bladder pain4
  • nausea4
  • urinary tract infection4
  • drug ineffective3
  • haematuria3
  • abdominal distension2
  • abdominal pain lower2
  • arthralgia2
  • bladder cancer recurrent2

Reports by year received

View as table
YearReports
202526
202623

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,110 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bladder cancer recurrent2863.7221.9967
bladder painSignal4541.5211.61,650
dysuriaSignal558.325.4228
pollakiuriaSignal551.522.4200
haematuriaSignal337.612.674
abdominal pain lower234.08.735
neutropeniaSignal1031.618.2268
chillsSignal725.612.9143
urinary tract infectionSignal410.13.924
anaemiaSignal49.03.521
abdominal distension28.22.17
pyrexiaSignal67.43.528
nausea42.20.82
arthralgia22.10.50
drug ineffective31.00.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.